J Oyee

1.3k total citations
38 papers, 887 citations indexed

About

J Oyee is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, J Oyee has authored 38 papers receiving a total of 887 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 11 papers in Pulmonary and Respiratory Medicine and 10 papers in Infectious Diseases. Recurrent topics in J Oyee's work include HIV/AIDS drug development and treatment (9 papers), Lung Cancer Treatments and Mutations (9 papers) and HIV Research and Treatment (6 papers). J Oyee is often cited by papers focused on HIV/AIDS drug development and treatment (9 papers), Lung Cancer Treatments and Mutations (9 papers) and HIV Research and Treatment (6 papers). J Oyee collaborates with scholars based in United Kingdom, Spain and United States. J Oyee's co-authors include Angela Boland, Rumona Dickson, A Bagust, Y Dündar, Tamara Brown, Paula Williamson, Munir Pirmohamed, Richard J. Fitzgerald, Andrea Jorgensen and Gerlinde Pilkington and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and British Journal of Cancer.

In The Last Decade

J Oyee

32 papers receiving 864 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J Oyee United Kingdom	17	266	205	139	117	109	38	887
Colleen Pelser United States	11	337 1.3×	48 0.2×	19 0.1×	114 1.0×	52 0.5×	16	828
G. Aulagner France	18	119 0.4×	141 0.7×	55 0.4×	35 0.3×	49 0.4×	79	1.2k
Ayse Aytaman United States	14	82 0.3×	61 0.3×	48 0.3×	55 0.5×	27 0.2×	33	1.0k
Anther Keung United States	14	384 1.4×	47 0.2×	130 0.9×	310 2.6×	14 0.1×	24	948
Clapton Dias United States	14	67 0.3×	187 0.9×	50 0.4×	40 0.3×	110 1.0×	20	1.4k
Insa Gathmann Switzerland	25	436 1.6×	178 0.9×	370 2.7×	95 0.8×	45 0.4×	44	4.4k
Brigitte Tranchand France	22	556 2.1×	152 0.7×	107 0.8×	29 0.2×	45 0.4×	50	1.2k
Bill Poland United States	10	245 0.9×	383 1.9×	22 0.2×	34 0.3×	75 0.7×	14	677
Taha Koray Şahin Türkiye	18	561 2.1×	270 1.3×	12 0.1×	137 1.2×	33 0.3×	83	1.1k
Marta Spreafico Italy	19	56 0.2×	80 0.4×	109 0.8×	61 0.5×	17 0.2×	38	976

Countries citing papers authored by J Oyee

Since Specialization

Citations

This map shows the geographic impact of J Oyee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J Oyee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J Oyee more than expected).

Fields of papers citing papers by J Oyee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J Oyee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J Oyee. The network helps show where J Oyee may publish in the future.

Co-authorship network of co-authors of J Oyee

This figure shows the co-authorship network connecting the top 25 collaborators of J Oyee. A scholar is included among the top collaborators of J Oyee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J Oyee. J Oyee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Joshi, Samit R., Mar Masiá, Essack Mitha, et al.. (2025). Efficacy and safety of the HIV-1 maturation inhibitor GSK3640254 plus dolutegravir as a two-drug regimen in adults naive to antiretroviral therapy (DYNAMIC): 24-week results from a randomised phase 2b study. EClinicalMedicine. 89. 103566–103566.

Tarzi, Ruth M., Jennifer A. McKenzie, J Oyee, et al.. (2025). Pharmaceutical Practice Considerations Regarding Adoption of the Race-Free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 Equations. American Journal of Kidney Diseases. 86(6). 843–853.

Ait‐Khaled, Mounir, et al.. (2024). Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based Regimen in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1: Subgroup Analysis of Participants With Elvitegravir as Baseline Third Agent From the TANGO Study. Open Forum Infectious Diseases. 11(5). ofae227–ofae227.

Underwood, Mark, Ruolan Wang, J Oyee, et al.. (2024). Dolutegravir + Lamivudine vs. Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Very-Low-Level HIV-1 Replication through 144 Weeks in the GEMINI-1 and GEMINI-2 Studies. Viruses. 16(3). 405–405. 2 indexed citations

Kumar, Princy, Amanda Clarke, Miguel García Deltoro, et al.. (2024). Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study. AIDS and Behavior. 29(1). 235–245.

Nan, Cassandra, Mark S. Shaefer, J Oyee, et al.. (2018). Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials. Open Forum Infectious Diseases. 5(5). ofy086–ofy086. 29 indexed citations

Pilkington, Gerlinde, Angela Boland, Tamara Brown, et al.. (2015). A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer. Thorax. 70(4). 359–367. 89 indexed citations

Greenhalgh, J, A Bagust, Angela Boland, et al.. (2014). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics. 33(2). 137–148. 14 indexed citations

Greenhalgh, J, A Bagust, Angela Boland, et al.. (2013). Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma. PharmacoEconomics. 31(5). 403–413. 24 indexed citations

10.

Fleeman, Nigel, Katherine Payne, William G. Newman, et al.. (2013). Are Health Technology Assessments of Pharmacogenetic Tests Feasible? A Case Study of CYP2D6 Testing in the Treatment of Breast Cancer with Tamoxifen. Personalized Medicine. 10(6). 601–611. 3 indexed citations

11.

Brown, Tamara, Gerlinde Pilkington, Angela Boland, et al.. (2013). Clinical effectiveness of first-line chemoradiation for adult patients with locally advanced non-small cell lung cancer: a systematic review. Health Technology Assessment. 17(6). 1–99. 38 indexed citations

12.

Hockenhull, Jo, Mary Gemma Cherry, James Mahon, et al.. (2012). A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy.. Health Technology Assessment. 16(12). III–IV, 1. 54 indexed citations

13.

Jorgensen, Andrea, Richard J. Fitzgerald, J Oyee, Munir Pirmohamed, & Paula Williamson. (2012). Influence of CYP2C9 and VKORC1 on Patient Response to Warfarin: A Systematic Review and Meta-Analysis. PLoS ONE. 7(8). e44064–e44064. 122 indexed citations

14.

Greenhalgh, J, A Bagust, Angela Boland, et al.. (2011). Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technology Assessment. 15(31). 1–178. 25 indexed citations

15.

Fleeman, Nigel, C Martin Saborido, Katherine Payne, et al.. (2011). The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.. Health Technology Assessment. 15(33). 1–102. 41 indexed citations

16.

Owens, Lynn, Graham P. Butcher, Ian Gilmore, et al.. (2011). A randomised controlled trial of extended brief intervention for alcohol dependent patients in an acute hospital setting (ADPAC). BMC Public Health. 11(1). 528–528. 8 indexed citations

17.

Dickson, Rumona, A Bagust, Angela Boland, et al.. (2011). Erlotinib Monotherapy for the Maintenance Treatment of Non-Small Cell Lung Cancer after Previous Platinum-Containing Chemotherapy. PharmacoEconomics. 29(12). 1051–1062. 40 indexed citations

18.

Fleeman, Nigel, A Bagust, Angela Boland, et al.. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. Health Technology Assessment. 15(42). 1–93, iii. 50 indexed citations

19.

Lux, Michael P., Michael Hartmann, Christian Jackisch, et al.. (2009). Cost-utility analysis for advanced breast cancer therapy in Germany: results of the fulvestrant sequencing model. Breast Cancer Research and Treatment. 117(2). 305–317. 22 indexed citations

20.

Karnon, Jonathan, et al.. (2008). Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Current Medical Research and Opinion. 24(6). 1609–1621. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact